Cite
HARVARD Citation
Shenderov, E. et al. (2021). Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial. Prostate. 81 (6), pp. 326-338. [Online].